by MM360 Staff | Feb 17, 2026 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
by MM360 Staff | Feb 17, 2026 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
by Andrea Lobo | Feb 16, 2026 | Myeloma News
Enrollment is now complete for an early clinical study assessing the safety and tolerability of SENTI-202, Senti Biosciences’ cell therapy candidate for adults with hard-to-treat acute myeloid leukemia (AML), a type of blood cancer. The Phase 1 trial (NCT06325748)...
by MM360 Staff | Feb 14, 2026 | Publications
Ther Adv Hematol. 2026 Feb 10;17:20406207261417132. doi: 10.1177/20406207261417132. eCollection 2026. ABSTRACT OBJECTIVE: This systematic literature review analyzed real-world evidence on autologous stem cell transplantation (ASCT) for newly diagnosed multiple myeloma...
by Andrea Lobo | Feb 13, 2026 | Myeloma News
The U.S. Food and Drug Administration (FDA) has approved Novocure’s Optune Pax, a type of Tumor Treating Fields (TTFields) therapy, as a treatment for locally advanced pancreatic cancer. The approval specifically covers the use of Optune Pax in combination with the...
